Keyphrases
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
100%
Chronic Kidney Disease
42%
Spain
41%
Fabry Disease
40%
Catalonia
36%
Tolvaptan
34%
Kidney Disease
33%
Alport Syndrome
25%
Pathogenic Variants
21%
Autosomal Dominant Alport Syndrome
21%
Disease Progression
21%
Genetic Kidney Disease
20%
Inherited Kidney Disease
17%
Migalastat
16%
Polycystic Kidney Disease
15%
Kidney
15%
Estimated Glomerular Filtration Rate
15%
Severe Influenza
15%
COL4A1
15%
International Workshop
14%
Induced Pluripotent Stem Cells (iPSCs)
14%
Pertussis
14%
Navarre
14%
Integration-free
14%
Rare Diseases
14%
Treatment Initiation
13%
Disease Activity Score
13%
Total Kidney Volume
13%
Phenotypic Spectrum
11%
Early Disease
11%
Genetic Testing
11%
Specific Treatment
10%
Fabry
10%
Kidney Disease Progression
10%
Therapeutic Intervention
10%
Chemoprophylaxis
10%
Household Contacts
10%
Nephrologists
10%
GLA Variants
10%
Chronic Kidney Disease Stage
9%
Molecular Diagnostics
9%
Enzyme Replacement Therapy
9%
Stem Cell Lines
9%
X-linked Disorder
9%
Dietary Intervention
8%
Medical Treatment
8%
Confidence Interval
8%
Genotype-phenotype Correlation
8%
COL4A5
8%
Patient-specific Therapy
8%
Medicine and Dentistry
Polycystic Kidney Disease
85%
Nephropathy
78%
Diseases
58%
Chronic Kidney Disease
43%
Fabry Disease
38%
Disease Exacerbation
29%
Tolvaptan
28%
Alport Syndrome
23%
Kidney Function
21%
Tuberous Sclerosis
21%
Autosomal Dominant Inheritance
18%
Nephrologist
17%
Glomerular Filtration Rate
16%
Migalastat
16%
Magnetic Resonance Imaging
15%
Pertussis
14%
Household
14%
Rare Disease
14%
Angiomyolipoma
14%
Diseases
14%
Renal Replacement Therapy
10%
Side Effect
10%
Kidney Injury
10%
Renal Failure
9%
Quality of Life
9%
Combination Therapy
9%
Enzyme Replacement Therapy
9%
Biological Marker
9%
Molecular Diagnosis
8%
Diet Therapy
8%
Genetic Screening
8%
Podocyte
8%
Chemoprophylaxis
8%
Clinical Management
8%
Hearing Impairment
8%
Nephrology
7%
Prospective Study
7%
Flank Pain
7%
Paroxysmal Nocturnal Hemoglobinuria
7%
Cardiovascular Risk
7%
Adenitis
7%
6 Diazo 5 Oxonorleucine
7%
Mucin 1
7%
Hemosiderin
7%
Rapamycin
7%
Leuprorelin
7%
Ganglion
7%
MYH9
7%
Aquaporin
7%
Cohort Analysis
7%